Known targets — ChEMBL curated mechanism
GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQ
The experimentally established mechanism targets of Midazolam. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 known ✓ | P14867 | 2/20 | 0.53 |
| ▸ | GABRA5 known ✓ | P31644 | 2/20 | 0.53 |
| ▸ | GABRA2 known ✓ | P47869 | 2/20 | 0.53 |
| ▸ | GABRG2 known ✓ | P18507 | 1/20 | 0.53 |
| ▸ | GABRB3 known ✓ | P28472 | 1/20 | 0.53 |
| ▸ | GABRA3 known ✓ | P34903 | 1/20 | 0.53 |
| ▸ | GABRB2 known ✓ | P47870 | 1/20 | 0.48 |
| ▸ | OPRK1 | P41145 | 3/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 1.00 |
| ▸ | PDE4D | Q08499 | 2/20 | 1.00 |
| ▸ | DRD3 | P35462 | 2/20 | 1.00 |
| ▸ | SLC22A1 | O15245 | 1/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 1/20 | 1.00 |
| ▸ | HTR2A | P28223 | 1/20 | 0.53 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.53 |
| ▸ | AURKA | O14965 | 1/20 | 0.53 |
| ▸ | PTAFR | P25105 | 1/20 | 0.51 |
| ▸ | HTR1A | P08908 | 1/20 | 0.51 |
| ▸ | HTR3A | P46098 | 1/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Midazolam SCHEMBL29357425 | 1.00 | OPRK1 (1.00) | OPRK1CYP3A4PDE4DDRD3SLC22A1 | |
| Midazolam SCHEMBL5783371 | 1.00 | OPRK1 (1.00) | OPRK1CYP3A4PDE4DDRD3SLC22A1 | |
| Midazolam SCHEMBL29735381 | 1.00 | OPRK1 (1.00) | OPRK1CYP3A4PDE4DDRD3SLC22A1 | |
| Midazolam SCHEMBL29565146 | 1.00 | OPRK1 (1.00) | OPRK1CYP3A4PDE4DDRD3SLC22A1 | |
| Midazolam SCHEMBL29480459 | 1.00 | OPRK1 (1.00) | OPRK1CYP3A4PDE4DDRD3SLC22A1 | |
| Midazolam SCHEMBL29419655 | 0.99 | OPRK1 (0.98) | OPRK1CYP3A4PDE4DDRD3SLC22A1 | |
| Midazolam SCHEMBL29445200 | 0.99 | OPRK1 (0.98) | OPRK1CYP3A4PDE4DDRD3SLC22A1 | |
| Midazolam SCHEMBL1311204 | 0.99 | OPRK1 (0.98) | OPRK1CYP3A4PDE4DDRD3SLC22A1 | |
| Midazolam SCHEMBL41265 | 0.99 | OPRK1 (0.98) | OPRK1CYP3A4PDE4DDRD3SLC22A1 | |
| Midazolam SCHEMBL15270674 | 0.99 | OPRK1 (0.98) | OPRK1CYP3A4PDE4DDRD3SLC22A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 35578 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3607938-B1 | PHARMACEUTICAL COMPOSITION | SOVIC BRKICIC LJILJANA (HR) | 2026-05-27 | — | — | EP | claimed |
| CN-122075410-A | Dry powder composition for intranasal delivery | — | 2026-05-26 | — | — | CN | claimed |
| CN-122087518-A | Method for classifying anesthetic drugs by using neural network | — | 2026-05-26 | — | — | CN | claimed |
| US-12629380-B2 | Oral film unit dosage form | SWIPP AB (SE) | 2026-05-19 | — | — | US | claimed |
| CN-122037215-A | Molecular imprinting hydrogen bond organic framework adsorption material and preparation method and application thereof | 重庆市食品药品检验检测研究院 | 2026-05-15 | — | — | CN | claimed |
| US-12624037-B2 | Method of treating agitation, aggressive behavior, and impulse control disorder | INTRA-CELLULAR THERAPIES, INC. (US) | 2026-05-12 | — | — | US | claimed |
| US-12624036-B2 | Method of treating post-traumatic stress disorder | INTRA-CELLULAR THERAPIES, INC. (US) | 2026-05-12 | — | — | US | claimed |
| WO-2026090360-A1 | FUSED PYRIMIDINE COMPOUNDS FOR TREATMENT OF TINNITUS, HEARING LOSS, AND MENIERE'S DISEASE | OVID THERAPEUTICS INC. (US) | 2026-04-30 | — | — | WO | claimed |
| US-20260108529-A1 | FUSED AMINO PYRIMIDINE COMPOUNDS FOR TREATMENT OF TINNITUS, ACUTE SENSORINEURAL HEARING LOSS, AGE-RELATED HEARING LOSS, AND MENIERE'S DISEASE | OVID THERAPEUTICS INC (US) | 2026-04-23 | — | — | US | claimed |
| US-20260102373-A1 | LYMPH DIRECTING PRODRUGS | MONASH UNIVERSITY (AU) | 2026-04-16 | — | — | US | claimed |
| WO-1990002737-A1 | NASAL ADMINISTRATION OF BENZODIAZEPINE HYPNOTICS | GOLDBERG ARTHUR H (US) | 1990-03-22 | — | — | WO | claimed |
| WO-1989010127-A1 | METHOD OF SAFELY PROVIDING ANESTHESIA OR CONSCIOUS SEDATION | BAKER CUMMINS PHARMACEUTICALS, INC. (US) | 1989-11-02 | — | — | WO | claimed |
| US-4873076-A | INTRAVENOUS ADMINISTRATION OF A BENZODIAZEPINE, OPIATE ANALGESIC AND A LONG-ACTING ANTAGONIST TO COUNTERACT DROP IN BLOOD PRESSURE | BAKER CUMMINS PHARMACEUTICALS, INC. (US) | 1989-10-10 | — | — | US | claimed |
| US-4832682-A | Injection method and apparatus with electrical blood absorbing stimulation | SURVIVAL TECHNOLOGY, INC. (US) | 1989-05-23 | — | — | US | claimed |
| US-4721709-A | Novel pharmaceutical compositions containing hydrophobic practically water-insoluble drugs adsorbed on pharmaceutical excipients as carrier; process for their preparation and the use of said compositions | PYARE SETH (CH) | 1988-01-26 | — | — | US | claimed |
| EP-0191771-A4 | Automatic injector assembly. | SURVIVAL TECHNOLOGY (US) | 1987-12-07 | — | — | EP | claimed |
| WO-1986006965-A1 | INJECTION METHOD AND APPARATUS WITH ELECTRICAL BLOOD ABSORBING STIMULATION | SURVIVAL TECHNOLOGY, INC. (US) | 1986-12-04 | — | — | WO | claimed |
| EP-0191771-A1 | Automatic injector assembly. | SURVIVAL TECHNOLOGY (US) | 1986-08-27 | — | — | EP | claimed |
| WO-1986001120-A1 | INJECTION METHOD AND APPARATUS WITH ELECTRICAL BLOOD ABSORBING STIMULATION | SURVIVAL TECHNOLOGY, INC. (US) | 1986-02-27 | — | — | WO | claimed |
| US-4280957-A | Imidazodiazepines and processes therefor | HOFFMANN-LA ROCHE INC. (US) | 1981-07-28 | — | — | US | claimed |